Ironwood Pharmaceuticals Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Ironwood Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IRWD, but not buy additional shares or sell existing shares.
View analyst ratings for Ironwood Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Ironwood Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ironwood Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Ironwood Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Ironwood Pharmaceuticals.

Ironwood Pharmaceuticals will be holding an earnings conference call on Thursday, August 5th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 416-621-4642 with passcode "2598317".

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) issued its quarterly earnings results on Thursday, May, 6th. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.22 by $0.02. The biotechnology company earned $88.80 million during the quarter, compared to analyst estimates of $87.94 million. Ironwood Pharmaceuticals had a net margin of 35.83% and a trailing twelve-month return on equity of 447.47%. The company's revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter last year, the business earned $0.04 EPS.
View Ironwood Pharmaceuticals' earnings history.

Ironwood Pharmaceuticals' stock was trading at $10.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, IRWD stock has increased by 23.8% and is now trading at $13.00.
View which stocks have been most impacted by COVID-19.

Ironwood Pharmaceuticals issued an update on its FY 2021 earnings guidance on Thursday, May, 27th. The company provided earnings per share guidance of - for the period. The company issued revenue guidance of $370 million-$385 million, compared to the consensus revenue estimate of $394.42 million.

4 brokerages have issued 1-year price objectives for Ironwood Pharmaceuticals' shares. Their forecasts range from $9.00 to $15.00. On average, they anticipate Ironwood Pharmaceuticals' share price to reach $12.00 in the next year. This suggests that the stock has a possible downside of 7.7%.
View analysts' price targets for Ironwood Pharmaceuticals or view top-rated stocks among Wall Street analysts.

7 employees have rated Ironwood Pharmaceuticals CEO Mark Mallon on Glassdoor.com. Mark Mallon has an approval rating of 93% among Ironwood Pharmaceuticals' employees. This puts Mark Mallon in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Ironwood Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR).
View all of IRWD's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), NIC (EGOV), Athabasca Oil (ATH), Allergan (AGN), Aegean Marine Petroleum Network (ANW), Micron Technology (MU) and Starbucks (SBUX).

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

Ironwood Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include New York State Common Retirement Fund (1.46%), Alliancebernstein L.P. (0.15%), Fisher Asset Management LLC (0.06%), Jackson Creek Investment Advisors LLC (0.06%), Victory Capital Management Inc. (0.03%) and Arizona State Retirement System (0.03%). Company insiders that own Ironwood Pharmaceuticals stock include Alexander J Denner, Gina Consylman, Jason Rickard, Julie Mchugh, Kelly Macdonald, Mark G Currie, Michael Shetzline, Thomas A Mccourt and Timothy M O'reilly.
View institutional ownership trends for Ironwood Pharmaceuticals.

IRWD stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, and Arizona State Retirement System. Company insiders that have sold Ironwood Pharmaceuticals company stock in the last year include Jason Rickard, Julie Mchugh, Kelly Macdonald, Mark G Currie, Michael Shetzline, and Thomas A Mccourt.
View insider buying and selling activity for Ironwood Pharmaceuticals or view top insider-selling stocks.

IRWD stock was acquired by a variety of institutional investors in the last quarter, including Jackson Creek Investment Advisors LLC, Fisher Asset Management LLC, Alliancebernstein L.P., Nelson Van Denburg & Campbell Wealth Management Group LLC, Victory Capital Management Inc., and Handelsbanken Fonder AB. Company insiders that have bought Ironwood Pharmaceuticals stock in the last two years include Alexander J Denner, and Timothy M O'reilly.
View insider buying and selling activity for Ironwood Pharmaceuticals or or view top insider-buying stocks.

Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IRWD stock can currently be purchased for approximately $13.00.

Ironwood Pharmaceuticals has a market capitalization of $2.11 billion and generates $389.52 million in revenue each year. The biotechnology company earns $106.18 million in net income (profit) each year or $0.79 on an earnings per share basis.

Ironwood Pharmaceuticals employs 232 workers across the globe.

The official website for Ironwood Pharmaceuticals is www.ironwoodpharma.com.

Ironwood Pharmaceuticals is headquartered at 100 SUMMER STREET SUITE 2300, BOSTON MA, 02110.

Ironwood Pharmaceuticals' mailing address is 100 SUMMER STREET SUITE 2300, BOSTON MA, 02110. The biotechnology company can be reached via phone at 617-621-7722 or via email at [email protected]